MYD88 and hepatocellular carcinoma: Previous studies demonstrated that TLR4/MyD88 activation might up‐regulate STAT3, which accelerates proliferation, metastasis and multidrug resistance of HCC (Kang et al., 2018; F. Wang et al., 2019).